George Aghajanian

From Wikipedia, the free encyclopedia

George Aghajanian
Born (1932-04-14) 14 April 1932 (age 89)
Beirut, Lebanon
Alma mater
Scientific career
Fields
InstitutionsYale School of Medicine

George K. Aghajanian is an Emeritus Foundations Fund Professor at the Yale School of Medicine,[1] New Haven, Connecticut, in the Department of Psychiatry. He has been a pioneer in the area of neuropharmacology. He has also served as a member of NARSAD Scientific Advisory Board.[2]

Early life and education[]

George Aghajanian was born on 14 April 1932 in Beirut, Lebanon. He received his B.A. from Cornell University, followed by his Doctor of Medicine at Yale University.

Research and career[]

Aghajanian did his research on the actions of LSD by which it produces hallucinations in the brain,[3] and he has also uncovered the therapeutic mechanism of atypical antipsychotic drugs.[4] He also found that application of serotonin (5-HT)[5] produces an increase in the frequency and amplitude of spontaneous excitatory postsynaptic potentials in layer V pyramidal cells of the neocortex and transitional cortex by whole-cell recording in rat brain slices. He did research on the structure and mechanism of psychotropic drugs and neurotransmitters.[6]

He was a medical officer in the United States Army in the starting days of his career.[7] He served different positions at the Yale School of Medicine, including Assistant Professor of Psychiatry, Professor of Psychiatry and Pharmacology, Foundations Fund Professor of research in Psychiatry.[8]

Awards and honors[]

Aghajanian received the CINP Pioneer Award from the International College of Neuropsychopharmacology.[9] He also received the for research on schizophrenia.[10] Additional awards include the Daniel H. Efron Research Award and the Julius Axelrod Mentorship Award from the American College of Neuropsychopharmacology,[11][12] the Scheele Award from the Swedish Academy of Pharmacy,[13] and the Heffter Award from the Heffter Research Institute,[14] and election to the National Academy of Medicine.[15]

Selected publications[]

  • George K Aghajanian: Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology.[16]
  • George Aghajanian, Benjamin S Bunney, and Philip S Holzman: Patricia Goldman-Rakic, 1937–2003. Neuropsychopharmacology.[17]
  • George K Aghajanian and Gerard J Marek: Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews.[18]
  • George K Aghajanian and Gerard J Marek: Serotonin–Glutamate Interactions: A New Target for Antipsychotic Drugs. Neuropsychopharmacology.[19]
  • George K.Aghajanian and Gerard J Marek: Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Research.[20]
  • Ronald S Duman, George K Aghajanian, Gerard Sanacora, and John H Krystal: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine.[21]
  • Ronald S Duman and George K Aghajanian: Neurobiology of Rapid Acting Antidepressants: Role of BDNF and GSK-3β. Neuropsychopharmacology.[22]
  • Ronald S. Duman and George K. Aghajanian: Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science.[23]

References[]

  1. ^ "George Aghajanian, MD". Yale School of Medicine. Retrieved 2 September 2019.
  2. ^ "Young Investigator Grant Program" (PDF).
  3. ^ "PsycNET". psycnet.apa.org. Retrieved 2 September 2019.
  4. ^ Gerard J. Marek; Aghajanian, George K. (1999). "Serotonin–Glutamate Interactions: A New Target for Antipsychotic Drugs". Neuropsychopharmacology. 21 (2): S122–S133. doi:10.1016/S0893-133X(99)00106-2. ISSN 1740-634X.
  5. ^ Aghajanian, G. K; Marek, G. J (1 April 1997). "Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells". Neuropharmacology. 36 (4): 589–599. doi:10.1016/S0028-3908(97)00051-8. ISSN 0028-3908. PMID 9225284. S2CID 46377649.
  6. ^ Psychotropic drugs and neurotransmitters, retrieved 2 September 2019
  7. ^ Medical school, military service and lsd, retrieved 2 September 2019
  8. ^ "George Aghajanian, MD". Yale School of Medicine. Retrieved 2 September 2019.
  9. ^ "Psychiatry@Yale June 2017". myemail.constantcontact.com. Retrieved 2 September 2019.
  10. ^ "George K. Aghajanian, M.D." Yale School of Medicine. Retrieved 2 September 2019.
  11. ^ "Daniel H. Efron Research Previous Award Winners". ACNP. Retrieved 2 September 2019.
  12. ^ "Julius Axelrod Mentorship Previous Award Winners". ACNP. Retrieved 2 September 2019.
  13. ^ "Former Laurates". Apotekarsocieteten. Retrieved 29 March 2020.
  14. ^ "Report from the Heffter Research Institute". maps.org. Retrieved 2 September 2019.
  15. ^ "George K. Aghajanian, M.D." National Academy of Medicine. Retrieved 29 March 2020.
  16. ^ Aghajanian, George K. (1 November 2009). "Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices". Psychopharmacology. 206 (4): 575–585. doi:10.1007/s00213-009-1484-9. ISSN 1432-2072. PMC 2755104. PMID 19241062.
  17. ^ Holzman, Philip S.; Bunney, Benjamin S.; Aghajanian, George (2003). "Patricia Goldman-Rakic, 1937–2003". Neuropsychopharmacology. 28 (12): 2218–2220. doi:10.1038/sj.npp.1300325. ISSN 1740-634X.
  18. ^ Aghajanian, George K; Marek, Gerard J (1 March 2000). "Serotonin model of schizophrenia: emerging role of glutamate mechanisms". Brain Research Reviews. 31 (2): 302–312. doi:10.1016/S0165-0173(99)00046-6. ISSN 0165-0173. PMID 10719157. S2CID 13040014.
  19. ^ Gerard J. Marek; Aghajanian, George K. (1999). "Serotonin–Glutamate Interactions: A New Target for Antipsychotic Drugs". Neuropsychopharmacology. 21 (2): S122–S133. doi:10.1016/S0893-133X(99)00106-2. ISSN 1740-634X.
  20. ^ Aghajanian, George K.; Marek, Gerard J. (17 April 1999). "Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release". Brain Research. 825 (1): 161–171. doi:10.1016/S0006-8993(99)01224-X. ISSN 0006-8993. PMID 10216183. S2CID 20081913.
  21. ^ Krystal, John H.; Gerard Sanacora; Aghajanian, George K.; Duman, Ronald S. (2016). "Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants". Nature Medicine. 22 (3): 238–249. doi:10.1038/nm.4050. ISSN 1546-170X. PMC 5405628. PMID 26937618.
  22. ^ George K. Aghajanian; Duman, Ronald S. (2014). "Neurobiology of Rapid Acting Antidepressants: Role of BDNF and GSK-3β". Neuropsychopharmacology. 39 (1): 233. doi:10.1038/npp.2013.217. ISSN 1740-634X. PMC 3857657. PMID 24317309.
  23. ^ Duman, Ronald S.; Aghajanian, George K. (5 October 2012). "Synaptic Dysfunction in Depression: Potential Therapeutic Targets". Science. 338 (6103): 68–72. doi:10.1126/science.1222939. ISSN 0036-8075. PMC 4424898. PMID 23042884.

External links[]

Retrieved from ""